Additionally, injecting AD brain-derived tau fibrils into the caudate putamen, instead of the hippocampus, poses a limitation, albeit it was a strategic choice based on the larger phosphorylated tau-positive area observed in our pilot studies. The gene discussed is MAPT; the disease is Alzheimer disease.